Biological and clinical heterogeneity of MYCN-amplified medulloblastoma

Focal high-level amplifications of MYC (or MYCC) define a subset of high-risk medulloblastoma patients. However, the prognostic role of MYCN oncogene amplification remains unresolved. We aimed to evaluate the prognostic value of this alteration alone and in combination with biological modifiers in 6...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Korshunov, Andrey (VerfasserIn) , Remke, Marc (VerfasserIn) , Kool, Marcel (VerfasserIn) , Hielscher, Thomas (VerfasserIn) , Witt, Hendrik (VerfasserIn) , Benner, Axel (VerfasserIn) , Deimling, Andreas von (VerfasserIn) , Kulozik, Andreas (VerfasserIn) , Westermann, Frank (VerfasserIn) , Lichter, Peter (VerfasserIn) , Pfister, Stefan (VerfasserIn)
Weitere Verfasser: Jones, David T. W. (BerichterstatterIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2012
In: Acta neuropathologica
Year: 2012, Jahrgang: 123, Heft: 4, Pages: 515-527
ISSN:1432-0533
DOI:10.1007/s00401-011-0918-8
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1007/s00401-011-0918-8
Verlag, Volltext: https://doi.org/10.1007/s00401-011-0918-8
Volltext
Verfasserangaben:Andrey Korshunov, Marc Remke, Marcel Kool, Thomas Hielscher, Paul A. Northcott, Dan Williamson, Elke Pfaff, Hendrik Witt, David T.W. Jones, Marina Ryzhova, Yoon-Jae Cho, Andrea Wittmann, Axel Benner, William A. Weiss, Andreas von Deimling, Wolfram Scheurlen, Andreas E. Kulozik, Steven C. Clifford, V. Peter Collins, Frank Westermann, Michael D. Taylor, Peter Lichter, Stefan M. Pfister

MARC

LEADER 00000caa a2200000 c 4500
001 1582432694
003 DE-627
005 20230427193220.0
007 cr uuu---uuuuu
008 181030s2012 xx |||||o 00| ||eng c
024 7 |a 10.1007/s00401-011-0918-8  |2 doi 
035 |a (DE-627)1582432694 
035 |a (DE-576)512432694 
035 |a (DE-599)BSZ512432694 
035 |a (OCoLC)1341022001 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Korshunov, Andrey  |e VerfasserIn  |0 (DE-588)1043235361  |0 (DE-627)770439365  |0 (DE-576)394592093  |4 aut 
245 1 0 |a Biological and clinical heterogeneity of MYCN-amplified medulloblastoma  |c Andrey Korshunov, Marc Remke, Marcel Kool, Thomas Hielscher, Paul A. Northcott, Dan Williamson, Elke Pfaff, Hendrik Witt, David T.W. Jones, Marina Ryzhova, Yoon-Jae Cho, Andrea Wittmann, Axel Benner, William A. Weiss, Andreas von Deimling, Wolfram Scheurlen, Andreas E. Kulozik, Steven C. Clifford, V. Peter Collins, Frank Westermann, Michael D. Taylor, Peter Lichter, Stefan M. Pfister 
264 1 |c 2012 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Published online: 9 December 2011 
500 |a Gesehen am 30.10.2018 
520 |a Focal high-level amplifications of MYC (or MYCC) define a subset of high-risk medulloblastoma patients. However, the prognostic role of MYCN oncogene amplification remains unresolved. We aimed to evaluate the prognostic value of this alteration alone and in combination with biological modifiers in 67 pediatric medulloblastomas with MYCN amplification (MYCN-MB). Twenty-one MYCN-MB were examined using gene expression profiling and array-CGH, whereas for 46 tumors immunohistochemical analysis and FISH were performed. All 67 tumors were further subjected to mutational analyses. We compared molecular, clinical, and prognostic characteristics both within biological MYCN-MB groups and with non-amplified tumors. Transcriptomic analysis revealed SHH-driven tumorigenesis in a subset of MYCN-MBs indicating a biological dichotomy of MYCN-MB. Activation of SHH was accompanied by variant-specific cytogenetic aberrations including deletion of 9q in SHH tumors. Non-SHH MB were associated with gain of 7q and isochromosome 17q/17q gain. Among clinically relevant variables, SHH subtype and 10q loss for non-SHH tumors comprised the most powerful markers of favorable prognosis in MYCN-MB. In conclusion, we demonstrate considerable heterogeneity within MYCN-MB in terms of genetics, tumor biology, and clinical outcome. Thus, assessment of disease group and 10q copy-number status may improve risk stratification of this group and may delineate MYCN-MB with the same dismal prognosis as MYC amplified tumors. Furthermore, based on the enrichment of MYCN and GLI2 amplifications in SHH-driven medulloblastoma, amplification of these downstream signaling intermediates should be taken into account before a patient is enrolled into a clinical trial using a smoothened inhibitor. 
650 4 |a Medulloblastoma 
650 4 |a 10q loss 
650 4 |a MYCN 
650 4 |a SHH pathway 
700 1 |a Remke, Marc  |d 1981-  |e VerfasserIn  |0 (DE-588)140368787  |0 (DE-627)618255133  |0 (DE-576)316618179  |4 aut 
700 1 |a Kool, Marcel  |e VerfasserIn  |0 (DE-588)1058669753  |0 (DE-627)797393560  |0 (DE-576)414823842  |4 aut 
700 1 |a Hielscher, Thomas  |e VerfasserIn  |0 (DE-588)1159594791  |0 (DE-627)1022977768  |0 (DE-576)50506068X  |4 aut 
700 1 |a Witt, Hendrik  |e VerfasserIn  |0 (DE-588)1043235884  |0 (DE-627)770439373  |0 (DE-576)394592085  |4 aut 
700 1 |a Jones, David T. W.  |0 (DE-588)1058669672  |0 (DE-627)79739334X  |0 (DE-576)414823583  |4 oth 
700 1 |a Benner, Axel  |d 1959-  |e VerfasserIn  |0 (DE-588)106584686X  |0 (DE-627)81687221X  |0 (DE-576)425536602  |4 aut 
700 1 |a Deimling, Andreas von  |d 1959-  |e VerfasserIn  |0 (DE-588)103034115X  |0 (DE-627)735093946  |0 (DE-576)378138065  |4 aut 
700 1 |a Kulozik, Andreas  |d 1959-  |e VerfasserIn  |0 (DE-588)1025736567  |0 (DE-627)723892032  |0 (DE-576)167091638  |4 aut 
700 1 |a Westermann, Frank  |d 1968-  |e VerfasserIn  |0 (DE-588)118119990  |0 (DE-627)69468628X  |0 (DE-576)291725570  |4 aut 
700 1 |a Lichter, Peter  |d 1957-  |e VerfasserIn  |0 (DE-588)1096366282  |0 (DE-627)856749915  |0 (DE-576)468019049  |4 aut 
700 1 |a Pfister, Stefan  |d 1974-  |e VerfasserIn  |0 (DE-588)123850215  |0 (DE-627)706450930  |0 (DE-576)293908400  |4 aut 
773 0 8 |i Enthalten in  |t Acta neuropathologica  |d Berlin : Springer, 1961  |g 123(2012), 4, Seite 515-527  |h Online-Ressource  |w (DE-627)253389666  |w (DE-600)1458410-4  |w (DE-576)072283092  |x 1432-0533  |7 nnas  |a Biological and clinical heterogeneity of MYCN-amplified medulloblastoma 
773 1 8 |g volume:123  |g year:2012  |g number:4  |g pages:515-527  |g extent:13  |a Biological and clinical heterogeneity of MYCN-amplified medulloblastoma 
856 4 0 |u http://dx.doi.org/10.1007/s00401-011-0918-8  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://doi.org/10.1007/s00401-011-0918-8  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20181030 
993 |a Article 
994 |a 2012 
998 |g 118119990  |a Westermann, Frank  |m 118119990:Westermann, Frank  |d 50000  |e 50000PW118119990  |k 0/50000/  |p 20 
998 |g 106584686X  |a Benner, Axel  |m 106584686X:Benner, Axel  |d 50000  |e 50000PB106584686X  |k 0/50000/  |p 13 
998 |g 123850215  |a Pfister, Stefan  |m 123850215:Pfister, Stefan  |d 910000  |d 910500  |e 910000PP123850215  |e 910500PP123850215  |k 0/910000/  |k 1/910000/910500/  |p 23  |y j 
998 |g 1096366282  |a Lichter, Peter  |m 1096366282:Lichter, Peter  |d 50000  |e 50000PL1096366282  |k 0/50000/  |p 22 
998 |g 1025736567  |a Kulozik, Andreas  |m 1025736567:Kulozik, Andreas  |d 910000  |d 910500  |e 910000PK1025736567  |e 910500PK1025736567  |k 0/910000/  |k 1/910000/910500/  |p 17 
998 |g 103034115X  |a Deimling, Andreas von  |m 103034115X:Deimling, Andreas von  |d 910000  |d 912000  |e 910000PD103034115X  |e 912000PD103034115X  |k 0/910000/  |k 1/910000/912000/  |p 15 
998 |g 1058669672  |a Jones, David T. W.  |m 1058669672:Jones, David T. W.  |d 50000  |e 50000PJ1058669672  |k 0/50000/  |p 9 
998 |g 1043235884  |a Witt, Hendrik  |m 1043235884:Witt, Hendrik  |d 910000  |d 910500  |e 910000PW1043235884  |e 910500PW1043235884  |k 0/910000/  |k 1/910000/910500/  |p 8 
998 |g 1159594791  |a Hielscher, Thomas  |m 1159594791:Hielscher, Thomas  |d 140000  |e 140000PH1159594791  |k 0/140000/  |p 4 
998 |g 1058669753  |a Kool, Marcel  |m 1058669753:Kool, Marcel  |d 50000  |e 50000PK1058669753  |k 0/50000/  |p 3 
998 |g 140368787  |a Remke, Marc  |m 140368787:Remke, Marc  |d 50000  |e 50000PR140368787  |k 0/50000/  |p 2 
998 |g 1043235361  |a Korshunov, Andrey  |m 1043235361:Korshunov, Andrey  |d 50000  |e 50000PK1043235361  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1582432694  |e 3030095746 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"physDesc":[{"extent":"13 S."}],"name":{"displayForm":["Andrey Korshunov, Marc Remke, Marcel Kool, Thomas Hielscher, Paul A. Northcott, Dan Williamson, Elke Pfaff, Hendrik Witt, David T.W. Jones, Marina Ryzhova, Yoon-Jae Cho, Andrea Wittmann, Axel Benner, William A. Weiss, Andreas von Deimling, Wolfram Scheurlen, Andreas E. Kulozik, Steven C. Clifford, V. Peter Collins, Frank Westermann, Michael D. Taylor, Peter Lichter, Stefan M. Pfister"]},"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Springer","dateIssuedDisp":"1961-","publisherPlace":"Berlin ; Heidelberg","dateIssuedKey":"1961"}],"pubHistory":["1.1961/62 -"],"title":[{"title":"Acta neuropathologica","title_sort":"Acta neuropathologica"}],"note":["Gesehen am 02.12.2005"],"id":{"eki":["253389666"],"issn":["1432-0533"],"zdb":["1458410-4"]},"recId":"253389666","language":["eng","ger"],"part":{"volume":"123","pages":"515-527","extent":"13","year":"2012","issue":"4","text":"123(2012), 4, Seite 515-527"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Biological and clinical heterogeneity of MYCN-amplified medulloblastomaActa neuropathologica"}],"recId":"1582432694","id":{"eki":["1582432694"],"doi":["10.1007/s00401-011-0918-8"]},"note":["Published online: 9 December 2011","Gesehen am 30.10.2018"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"2012","dateIssuedKey":"2012"}],"person":[{"display":"Korshunov, Andrey","given":"Andrey","family":"Korshunov","role":"aut"},{"display":"Remke, Marc","given":"Marc","family":"Remke","role":"aut"},{"family":"Kool","given":"Marcel","display":"Kool, Marcel","role":"aut"},{"role":"aut","given":"Thomas","family":"Hielscher","display":"Hielscher, Thomas"},{"role":"aut","display":"Witt, Hendrik","family":"Witt","given":"Hendrik"},{"role":"oth","given":"David T. W.","family":"Jones","display":"Jones, David T. W."},{"display":"Benner, Axel","given":"Axel","family":"Benner","role":"aut"},{"role":"aut","display":"Deimling, Andreas von","family":"Deimling","given":"Andreas von"},{"role":"aut","family":"Kulozik","given":"Andreas","display":"Kulozik, Andreas"},{"display":"Westermann, Frank","family":"Westermann","given":"Frank","role":"aut"},{"display":"Lichter, Peter","family":"Lichter","given":"Peter","role":"aut"},{"given":"Stefan","family":"Pfister","display":"Pfister, Stefan","role":"aut"}],"title":[{"title":"Biological and clinical heterogeneity of MYCN-amplified medulloblastoma","title_sort":"Biological and clinical heterogeneity of MYCN-amplified medulloblastoma"}]} 
SRT |a KORSHUNOVABIOLOGICAL2012